For this, we transfected the human PC-3 (p53 null) prostate cancer cells with plasmid pCMV-Neo-Bam, pCMV-Neo-Bam-WT p53, pCMV-Neo-Bam-p53P223L or pCMV-Neo-Bam-p53V274F, confirmed the expression of p53 mutants in these isogenic cells by western blotting (Fig. 4a) and then treated the cells with PEITC. The gene discussed is TP53; the disease is prostate carcinoma.